KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Interest & Investment Income for 15 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 14.15% year-over-year to $26.6 million, compared with a TTM value of $111.5 million through Dec 2025, down 8.63%, and an annual FY2025 reading of $111.5 million, down 8.63% over the prior year.
  • Interest & Investment Income was $26.6 million for Q4 2025 at Alnylam Pharmaceuticals, down from $28.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $32.1 million in Q3 2024 and bottomed at $225000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $17.8 million, with a median of $23.2 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income crashed 91.79% in 2021, then skyrocketed 3375.56% in 2022.
  • Year by year, Interest & Investment Income stood at $495000.0 in 2021, then skyrocketed by 2743.84% to $14.1 million in 2022, then skyrocketed by 116.0% to $30.4 million in 2023, then increased by 2.02% to $31.0 million in 2024, then fell by 14.15% to $26.6 million in 2025.
  • Business Quant data shows Interest & Investment Income for ALNY at $26.6 million in Q4 2025, $28.7 million in Q3 2025, and $27.5 million in Q2 2025.